Camidge, R., Heist, R. S., Goldman, J., Angevin, E., Strickler, J., Morgensztern, D., … Kelly, K. (2018). An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC). In Ann Oncol (Vol. 29 Suppl 8, pp. viii496–viii497). England. https://doi.org/10.1093/annonc/mdy292.006

Camidge, R., R. S. Heist, J. Goldman, E. Angevin, J. Strickler, D. Morgensztern, M. Barve, et al. “An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC).” In Ann Oncol, 29 Suppl 8:viii496–97, 2018. https://doi.org/10.1093/annonc/mdy292.006.

Camidge R, Heist RS, Goldman J, Angevin E, Strickler J, Morgensztern D, et al. An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC). In: Ann Oncol. 2018. p. viii496–7.

Camidge, R., et al. “An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC).” Ann Oncol, vol. 29 Suppl 8, 2018, pp. viii496–97. Pubmed, doi:10.1093/annonc/mdy292.006.

Camidge R, Heist RS, Goldman J, Angevin E, Strickler J, Morgensztern D, Barve M, Bauer TM, Vokes EE, Yi T, Motwani M, Parikh A, Wu J, Kelly K. An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC). Ann Oncol. 2018. p. viii496–viii497.